Medpace Holdings, Inc. (MEDP)
NasdaqGS · USD · Healthcare · Diagnostics & Research
$676.77 (+1.13%) as of
Key statistics
- Market cap
- 18.93B
- P/E (TTM)
- 37.16
- Forward P/E
- 34.09
- EPS (TTM)
- 18.21
- Dividend yield
- 0.00%
- 52-week range
- 373.00 – 684.52
- Beta
- 1.18
- Revenue (TTM)
- 2.84B
- Profit margin
- 18.24%
- Analyst target
- $644.77
- Volume
- 305.67k
About Medpace Holdings, Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Cincinnati, OH, United States
- Employees
- 6,600
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.